+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cardiovascular Drugs Market by Drug Type (Angiotensin Inhibitors, Anticoagulants, Antihyperlipidemic), Disease Indication (Arrhythmia, Coronary Artery Disease, Hyperlipidaemia), Route of Administration, Mode of Purchase, End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666022
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cardiovascular Drugs Market grew from USD 82.65 billion in 2023 to USD 90.13 billion in 2024. It is expected to continue growing at a CAGR of 9.15%, reaching USD 152.61 billion by 2030.

This includes a variety of therapeutic drug classes, such as antihypertensives, anticoagulants, antiarrhythmics, antianginals, and cholesterol-lowering drugs. These medications are primarily used in the clinical management of conditions such as hypertension, hyperlipidemia, coronary artery disease, arrhythmias, and heart failure. The increasing incidence of cardiovascular conditions globally, especially among the aging population, is expanding the need for cardiovascular drugs. Rising healthcare spending and improvements in healthcare infrastructure in emerging economies are propelling market expansion. Adverse drug reactions and safety concerns lead to product recalls and tarnish the brand image, subsequently impacting the market growth. New advances in personalized medicine and biologics are presenting significant opportunities in the cardiovascular drug market. Additionally, rising research & development activities to introduce novel cardiovascular are expected to fuel the market growth.

Regional Insights

The Americas maintain a significant position in the global cardiovascular drugs market because of high healthcare expenditure, sophisticated healthcare infrastructure, and significant research and development activities. The U.S. market exhibits strong demand for innovative and branded drugs bolstered by a consumer base that prioritizes efficacy and brand reputation. The European Union (EU) countries exhibit a strong demand for cardiovascular drugs with a large aging population. Market dynamics in the EU are shaped by rigorous regulations and the presence of numerous global pharmaceutical players. There is a mix of preference for brand-name drugs and generics driven by cost-containment measures within various healthcare systems. In the Middle East and Africa, the market for cardiovascular drugs is evolving with rising incidence rates of heart diseases. The Asia Pacific region is rapidly emerging as a significant market for cardiovascular drugs, driven by a growing aging population and an increasing prevalence of cardiovascular diseases (CVDs). In this region, China and India are significant countries due to their large populations and the burgeoning incidence of CVDs. In terms of consumer needs, access to affordable healthcare and generic medicine is paramount due to diverse economic strata across the region.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Cardiovascular Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Rising Prevalence of Cardiovascular Disorders
  • Increasing R&D Investments for Drug Development
  • Government Initiatives for Prevention & Control of Cardiovascular Diseases

Market Restraints

  • Product Recalls and High Cost of Cardiovascular Drugs

Market Opportunities

  • Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
  • Introduction of Novel Drugs for Treatment of Cardiovascular Diseases

Market Challenges

  • Complexities in Efficient and Safe Drug Development

Market Segmentation Analysis

  • Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
  • Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
  • Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
  • End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiovascular Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiovascular Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases

Bristol Myers Squibb has invested over USD 100 million to enhance its collaboration with Avidity Biosciences. This strategic move underscores Bristol Myers' confidence in Avidity's innovative RNA-based therapy platform. This bold expansion marks a significant milestone in Bristol Myers Squibb’s quest to revolutionize the future landscape of cardiovascular medicine.

U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure

In a significant development for Lexicon Pharmaceuticals Inc., the U.S. Food and Drug Administration (FDA) has officially approved the company's novel oral medication, sotagliflozin, to be marketed as Inpefa for the expansive treatment of heart failure, including for those patients living with type 2 diabetes. This approval marks a milestone for Lexicon, as sotagliflozin represents the first drug by Lexicon to receive endorsement from the FDA, an achievement accentuated by the drug's prior unsuccessful attempt to secure approval as a supplementary treatment to insulin for type 1 diabetes.

Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

Glenmark Pharmaceuticals has announced the Indian market launch of its novel combination therapy, 'Sacu V', a tablet containing sacubitril and valsartan, expressly indicated for heart failure treatment. Upholding a cost-effective strategy, 'Sacu V' is offered at a competitive price, with the 50mg dosage variant (comprising 24mg of sacubitril and 26mg of valsartan) available at INR 19 per tablet.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiovascular Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Auro Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Chiesi USA, Inc., Cipla Limited, Cornerstone Therapeutics Inc., CYTOKINETICS, Incorporated, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Par Pharmaceutical by Endo International, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., WellSpring Pharmaceutical Corporation, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type

  • Angiotensin Inhibitors
  • Anticoagulants
  • Antihyperlipidemic
  • Antihypertensive
  • Antiplatelet Drugs

Disease Indication

  • Arrhythmia
  • Coronary Artery Disease
  • Hyperlipidaemia
  • Hypertension

Route of Administration

  • Intravenous
  • Oral
  • Subcutaneous

Mode of Purchase

  • Over-The-Counter Drugs
  • Prescription-Based Drugs

End-Users

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Cardiovascular Disorders
5.1.1.2. Increasing R&D Investments for Drug Development
5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
5.1.2. Restraints
5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
5.1.3. Opportunities
5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
5.1.4. Challenges
5.1.4.1. Complexities in Efficient and Safe Drug Development
5.2. Market Segmentation Analysis
5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Cardiovascular Drugs Market, by Drug Type
6.1. Introduction
6.2. Angiotensin Inhibitors
6.3. Anticoagulants
6.4. Antihyperlipidemic
6.5. Antihypertensive
6.6. Antiplatelet Drugs
7. Cardiovascular Drugs Market, by Disease Indication
7.1. Introduction
7.2. Arrhythmia
7.3. Coronary Artery Disease
7.4. Hyperlipidaemia
7.5. Hypertension
8. Cardiovascular Drugs Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Cardiovascular Drugs Market, by Mode of Purchase
9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription-Based Drugs
10. Cardiovascular Drugs Market, by End-Users
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas Cardiovascular Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Cardiovascular Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Cardiovascular Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
14.3.2. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
14.3.3. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CARDIOVASCULAR DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 83. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 84. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 85. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 86. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 87. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 88. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 89. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 90. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 91. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 92. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 93. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 94. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 95. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 96. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 97. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 98. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 99. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 100. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 101. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 102. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 137. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 138. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 139. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 140. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 141. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 142. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 143. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 144. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 145. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 146. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 147. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 148. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 149. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 150. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 151. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 152. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 153. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 154. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 155. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 156. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 165. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 166. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 167. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 168. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 169. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 171. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 172. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 173. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 174. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 175. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 176. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 185. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 186. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 195. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 196. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 205. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 206. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 215. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 216. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 225. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 226. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 227. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 228. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 229. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 230. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 231. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 232. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 233. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 234. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 235. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 236. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 245. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 246. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 259. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 260. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 261. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 262. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 263. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 264. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 265. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 266. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 267. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 268. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 269. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 270. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 271. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 272. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 273. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 274. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 275. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 276. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 277. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 278. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 279. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 280. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 281. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 282. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 283. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 284. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 285. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 286. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 287. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 288. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 289. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 290. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 291. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 292. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 293. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 294. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 295. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 296. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 297. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 298. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 299. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 300. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 301. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 302. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 303. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 304. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 305. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 306. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 307. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 308. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 309. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 310. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 311. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 312. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 313. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 314. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 317. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 318. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 319. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 320. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 321. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 322. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 323. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 324. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 325. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
TABLE 326. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
TABLE 327. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 328. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 329. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
TABLE 330. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
TABLE 331. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
TABLE 332. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
TABLE 333. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRA

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Apotex Inc.
  • AstraZeneca PLC
  • Auro Pharma Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Chiesi USA, Inc.
  • Cipla Limited
  • Cornerstone Therapeutics Inc.
  • CYTOKINETICS, Incorporated
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Par Pharmaceutical by Endo International
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • WellSpring Pharmaceutical Corporation
  • Zydus Group

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 90.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 152.61 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal

Related Topics

Related Reports

Cardiovascular Drugs - Global Strategic Business Report - Product Image

Cardiovascular Drugs - Global Strategic Business Report

  • Report
  • 413 Pages
  • Global
From
Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration (Oral Anticoagulants, Injectable Anticoagulants), By Drug Category, By Application (Atrial fibrillation, Pulmonary embolism), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Global Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Forecast 2024-2030 - Product Image

Global Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Anticoagulants Global Market Report 2024 - Product Image

Anticoagulants Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets - Product Image

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

  • Report
  • 157 Pages
  • Global
From

About the Cardiovascular Drugs Market

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.